Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 4
1988 1
1989 1
1990 3
1991 3
1992 1
1993 1
1995 1
1998 1
2000 4
2002 1
2004 1
2009 1
2011 1
2023 3
2024 3
2025 9
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression.
Shimizu T, Ohkuma R, Homma M, Nakayama S, Sasaki Y, Muto S, Ieguchi K, Watanabe M, Taguchi A, Takayanagi D, Wada Y, Horiike A, Kubota Y, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Mura E, Yoshimura K, Tsuji M, Kiuchi Y, Suzuki H, Yamochi T. Shimizu T, et al. Among authors: iriguchi n. Front Immunol. 2025 Sep 8;16:1528594. doi: 10.3389/fimmu.2025.1528594. eCollection 2025. Front Immunol. 2025. PMID: 40990022 Free PMC article.
Ki-67 expression in anti-programmed cell death protein-1 antibody-bound CD8+ T cells as a predictor of clinical benefit.
Tsurui T, Hosonuma M, Sasaki A, Maruyama Y, Amari Y, Funayama E, Tajima K, Toyoda H, Isobe J, Yamazaki Y, Baba Y, Shida M, Udaka Y, Mura E, Suzuki R, Iriguchi N, Ishiguro T, Hirasawa Y, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Wada S, Kuramasu A, Tsuji M, Kiuchi Y, Tsunoda T, Yoshimura K. Tsurui T, et al. Among authors: iriguchi n. Discov Oncol. 2025 Mar 18;16(1):348. doi: 10.1007/s12672-025-02060-x. Discov Oncol. 2025. PMID: 40100476 Free PMC article.
Elevated plasma levels of WAP four-disulfide core domain 2 as a potential prognostic biomarker for various cancers.
Watanabe M, Ieguchi K, Onishi N, Shimizu T, Ohkuma R, Suzuki R, Mura E, Iriguchi N, Ishiguro T, Hirasawa Y, Ikeda G, Shimokawa M, Ariizumi H, Horiike A, Yoshimura K, Tsunoda T, Tsuji M, Kobayashi S, Kiuchi Y, Wada S. Watanabe M, et al. Among authors: iriguchi n. Front Oncol. 2025 Jul 14;15:1614102. doi: 10.3389/fonc.2025.1614102. eCollection 2025. Front Oncol. 2025. PMID: 40727473 Free PMC article.
Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study.
Tsurui T, Hamada K, Mura E, Suzuki R, Iriguchi N, Ishiguro T, Hirasawa Y, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Wada S, Yoshimura K, Tsuji M, Kiuchi Y, Tsunoda T. Tsurui T, et al. Among authors: iriguchi n. Front Oncol. 2025 Feb 6;15:1499650. doi: 10.3389/fonc.2025.1499650. eCollection 2025. Front Oncol. 2025. PMID: 39980541 Free PMC article.
Veillonella and Streptococcus are associated with aging of the gut microbiota and affect the efficacy of immune checkpoint inhibitors.
Hirasawa Y, Isobe J, Hosonuma M, Tsurui T, Baba Y, Funayama E, Tajima K, Murayama M, Narikawa Y, Toyoda H, Shida M, Sasaki A, Maruyama Y, Amari Y, Mura E, Suzuki R, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Sambe T, Uchida N, Wada S, Kobayashi S, Kiuchi Y, Kuramasu A, Yoshimura K, Tsunoda T. Hirasawa Y, et al. Among authors: iriguchi n. Front Immunol. 2025 May 22;16:1528521. doi: 10.3389/fimmu.2025.1528521. eCollection 2025. Front Immunol. 2025. PMID: 40475781 Free PMC article.
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy.
Ohkuma R, Fujimoto Y, Ieguchi K, Onishi N, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Sasaki Y, Homma M, Yamochi T, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Among authors: iriguchi n. Oncol Lett. 2023 Jul 20;26(3):381. doi: 10.3892/ol.2023.13967. eCollection 2023 Sep. Oncol Lett. 2023. PMID: 37559573 Free PMC article.
Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors.
Ohkuma R, Miura S, Muto S, Toyomasu Y, Fujimoto Y, Ieguchi K, Onishi N, Shimizu T, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Mura E, Takenoshita S, Numajiri K, Okabe N, Yoshimura K, Tsuji M, Kiuchi Y, Yajima T, Ishida H, Suzuki H, Yamochi T, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Among authors: iriguchi n. Front Immunol. 2023 Sep 18;14:1260492. doi: 10.3389/fimmu.2023.1260492. eCollection 2023. Front Immunol. 2023. PMID: 37790929 Free PMC article.
Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model.
Goshima T, Ieguchi K, Onishi N, Shimizu T, Takayanagi D, Watanabe M, Fujimoto Y, Ohkuma R, Suzuki R, Tsurui T, Mura E, Iriguchi N, Ishiguro T, Shimokawa M, Hirasawa Y, Kubota Y, Ariizumi H, Horiike A, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Fujishiro J, Hoffman RM, Tsunoda T, Wada S. Goshima T, et al. Among authors: iriguchi n. Anticancer Res. 2024 Jan;44(1):23-29. doi: 10.21873/anticanres.16784. Anticancer Res. 2024. PMID: 38159965
Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment.
Hirasawa Y, Kubota Y, Mura E, Suzuki R, Tsurui T, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Horiike A, Wada S, Ariyoshi T, Goto S, Otsuka K, Murakami M, Kiuchi Y, Yoshimura K, Hoffman RM, Tsunoda T. Hirasawa Y, et al. Among authors: iriguchi n. Anticancer Res. 2024 Aug;44(8):3397-3407. doi: 10.21873/anticanres.17160. Anticancer Res. 2024. PMID: 39060084
Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patients.
Hirasawa Y, Kubota Y, Mura E, Suzuki R, Tsurui T, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Horiike A, Wada S, Yamashita T, Ariyoshi T, Goto S, Otsuka K, Murakami M, Kiuchi Y, Yoshimura K, Tsunoda T. Hirasawa Y, et al. Among authors: iriguchi n. Front Oncol. 2024 Oct 11;14:1449941. doi: 10.3389/fonc.2024.1449941. eCollection 2024. Front Oncol. 2024. PMID: 39464714 Free PMC article.
40 results